Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose in HFpEF with iron deficiency
NCT05477498Phase 4Withdrawn
- Sponsor
- Kantonsspital Baselland
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of ferric carboxymaltose in heart failure with preserved ejection fraction (HFpEF), iron deficiency anemia (IDA), sponsored by Kantonsspital Baselland. Planned start Dec 2021; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05477498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477498.